Antibody-mediated capture of amyloid-beta (Aβ) in peripheral blood was identified as an
attractive strategy to eliminate cerebral toxic amyloid in Alzheimer's disease (AD) patients …

The role of microglia in the removal of amyloid deposits after systemically administered anti-
Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic …

Many new therapeutics for Alzheimer's disease delay the accumulation of amyloid-β (Aβ) in
transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we …

Alzheimer's disease is a major health problem with limited available medical treatment
options. Immunotherapy is one approach with the potential to slow or reverse the disease …

Vaccination therapy of AD animal models and patients strongly suggests an active role of
brain mononuclear phagocytes in immune-mediated clearance of amyloid-β peptides (Aβ) in …

Given the compelling genetic and biochemical evidence that has implicated amyloid-β (Aβ)
in the pathogenesis of Alzheimer's disease, many studies have focused on ways to inhibit …

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and the most
common form of dementia among the elderly. As the population grows and lifespan is …

Although extracellular Aβ plaques are a hallmark of Alzheimer's disease, it remains to be
determined whether extracellular or intracellular Aβ accumulation initiates the disease …

Immunotherapeutic efforts to slow the clinical progression of Alzheimer's disease (AD) by
lowering brain amyloid-β (Aβ) have included Aβ vaccination, intravenous immunoglobulin …

BACKGROUND: Passive immunization for the treatment of Alzheimer's disease (AD) was
rapidly translated into clinical trials. However, basic mechanisms of AD immunotherapy …